Last reviewed · How we verify
Short bowel syndrome — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Gattex Kit | TEDUGLUTIDE | Takeda | GLP-2 Analog [EPC] | Glucagon-like peptide 2 receptor | 2012-01-01 | |
| Nutrestore | GLUTAMINE | Emmaus Medcl | Amino Acid [EPC] | 2004-01-01 | ||
| Glutamin | Glutamin | Shahid Beheshti University | Amino acid transporter |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Emmaus Medcl · 1 drug in Short bowel syndrome
- Shahid Beheshti University · 1 drug in Short bowel syndrome
- Takeda · 1 drug in Short bowel syndrome
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Short bowel syndrome:
- Short bowel syndrome treatment updates — RSS
- Short bowel syndrome treatment updates — Atom
- Short bowel syndrome treatment updates — JSON
Cite this brief
Drug Landscape (2026). Short bowel syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/short-bowel-syndrome. Accessed 2026-06-10.
Related
- Short bowel syndrome full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing